AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

This article helps to dispel myths related to rheumatoid arthritis (RA) and raise awareness regarding it. From causes to ...

PORTLAND, KS, UNITED STATES, February 13, 2025 /EINPresswire / -- Rheumatoid arthritis is an autoimmune disorder, w ...

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...

The vagus nerve, a complex bundle of 200,000 fibers connecting the brain to vital organs, has remained a medical enigma for ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Kuick Research Report Highlights Ongoing Developments In Molecular Switches Application Therapeutic Targets & Drug Delivery ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

ANSWER: Both RA and MCTD are rheumatologic diseases that affect many systems of the body. MCTD is often considered an overlap ...

Bringing together experts from different fields is how you find true innovation to improve patient care, according to award-winning assistant ...

Anesthesia does not cause dementia. However, some people do develop a complication called post-operative delirium.